

## Davidson, Mark

---

**From:** Davidson, Mark  
**Sent:** Thursday, September 21, 2017 2:38 PM  
**To:** Rizwana Sproule (RSproule@KitePharma.com)  
**Cc:** 'Alex Babayan'; 'Nadia Agopyan'  
**Subject:** Kite Pharma 125643 Clinical IR 9.21.17

**Importance:** High

Dr. Sproule,

Of the ZUMA-1 phase 2 patients, 8 of the 111 patients who underwent leukapheresis did not receive conditioning chemotherapy. Per CSR Section 10.3, 1 subject (101-003-017) had leukapheresis but not conditioning because of manufacturing failure. Yet, CSR Section 10.2, CSR Table 11, and ADSL.xpt do not mention manufacturing failure; instead, the CSR's stated reasons for the 8 patients not receiving conditioning are 2 deaths from PD, 4 post-leukapheresis SAEs, and 2 patients with non-measurable disease. Resolve the discrepancies in the reported reasons for not receiving conditioning.

**Please respond by tomorrow, Friday, Sept 22, 2017 at 12 pm EST.**

Best

Mark L. Davidson, RHIA  
Regulatory Project Manager  
OTAT/CBER/FDA  
10903 New Hampshire Avenue  
Silver Spring, MD 20993-0002  
Phone: 240-402-8277  
Fax:301-595-1303  
[mark.davidson@fda.hhs.gov](mailto:mark.davidson@fda.hhs.gov)

"THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone."